Sodium hyaluronate dry powder inhalation in combination with sodium cromoglycate prepared using optimized spray drying conditions

Basit Öğe Kaydı
dc.authoridyıldız türkyılmaz, gülbeyaz/0000-0002-8601-0263
dc.authoridALPARSLAN, LEVENT/0000-0003-0113-6850
dc.authorwosidyıldız türkyılmaz, gülbeyaz/AAF-7766-2019
dc.contributor.authorTurkyilmaz, Guelbeyaz Yildiz
dc.contributor.authorOzdokur, Kemal Volkan
dc.contributor.authorAlparslan, Levent
dc.contributor.authorKarasulu, Ercument
dc.date.accessioned2024-05-19T14:46:42Z
dc.date.available2024-05-19T14:46:42Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractSodium hyaluronate (SHA) is an anti-inflammatory and protective agent against bronchoconstriction, and sodium cromoglicate (SCG) prevents exercise-induced bronchoconstriction and inflammation. Based on the pharmacological properties of both substances, this study aimed to develop a dry powder inhaler (DPI) of SHA alone and in combination with SCG. The target of the study was to develop flowable formulations without any surfactants by using the spray drying method. To obtain respirable SHA and SCG:SHA particles, variables of the spray dryer, such as inlet temperature, atomized air flow, and feed solution, were changed. The particles 1-8 mu m in size were produced with high yield by spray drying and increasing the ethanol percentage of the feed solution (60%), which is the most remarkable parameter. After that, physicochemical characterizations were performed. The aerosol performance of DPI formulations prepared using lactose was evaluated using Handihaler (R) DPI. The fine particle fraction (FPF) was 36% for the SHA formulation, whereas it was 52 and 53% for SCG and SHA, respectively, in the SCG:SHA formulation. Consequently, both particles were produced reproducibly by spray drying, and inhaled SHA and SCG:SHA dry powder formulations were developed due to their high FPF and flowability with lactose.en_US
dc.description.sponsorshipNEUTEC ILAC SAN; TIC.A.S. (NEUTEC)en_US
dc.description.sponsorshipThe authors acknowledge the support of NEUTEC ILAC SAN. TIC.A.S. (NEUTEC) for providing insight into the study, financial sup-port, advice, and assistance on the use of the inhaler quality control laboratory. We are grateful to Ege University Planning and Monitoring Coordination of Organizational Development and Directorate of Library and Documentation for their support in editing and proofreading service of this studyen_US
dc.identifier.doi10.1080/10837450.2023.2176517
dc.identifier.endpage247en_US
dc.identifier.issn1083-7450
dc.identifier.issn1097-9867
dc.identifier.issue2en_US
dc.identifier.pmid36730066en_US
dc.identifier.scopus2-s2.0-85147713715en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage240en_US
dc.identifier.urihttps://doi.org10.1080/10837450.2023.2176517
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5577
dc.identifier.volume28en_US
dc.identifier.wosWOS:000929207700001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofPharmaceutical Development and Technologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectSodium Hyaluronateen_US
dc.subjectSodium Cromoglycateen_US
dc.subjectSpray Dryeren_US
dc.subjectDry Powder Inhaleren_US
dc.subjectBronchoconstrictionen_US
dc.subjectAnti-Inflammationen_US
dc.titleSodium hyaluronate dry powder inhalation in combination with sodium cromoglycate prepared using optimized spray drying conditionsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu